Provider review
Embody review
Two of the lowest figures here, both marked promotional, against a standing rate never printed.
The products are labeled by receptor rather than by drug, so what molecule the lower figure buys is not something the page states.
Reviewed by Lena OrtizMetabolic Health Editor
Price updated August 2026
How we’re funded. Some links here are affiliate links: start care through one and we may earn a commission, at no extra cost to you. Affiliate partners are listed first on our rankings — what we write about a provider is the same either way, and unflattering findings about one that pays us stay in. Full disclosure.
Price as published
Embody
$79/mo GLP-1 · $129/mo GLP-1 with GIP, promo applied
- Vs median
- $90/mo below the $169 median
- Market
- $59–$1300/mo across 242 of 373
- Structure
- Standard plan, self-directed low dose
- Dispensed
- Pharmacy not publicly identified
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
In one paragraph
The verdict
These are among the lowest published monthly figures of any provider here, and two things need saying before a reader treats them that way. The first is the banner: the site announces a summer promotion already applied to the prices shown, and quantifies the saving at a sum larger than either price. That makes both figures promotional, and the rate they revert to is not printed anywhere — so a reader can see what the first months cost and cannot see what the year costs. The second is what the products are called. Embody labels them by receptor rather than by drug, selling a GLP-1 injection and a GLP-1 with GIP injection. In this category a dual agonist at that price point is nearly always tirzepatide, but nearly always is an inference and the page does not make the statement, so this review does not make it either. That matters more here than it would elsewhere, because the reason to know the molecule is to know what dose you are holding and what a small one ought to cost. Neither figure carries a milligram in any case. What the site does state plainly deserves credit: the medication is inside the price rather than billed beside it, there is no membership, and a patient already on treatment elsewhere can transfer at their current dose if they can show the prescription — a genuinely useful policy for someone who has titrated down and wants to stay there rather than restart a ladder.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
Who it suits, and who it does not
A good fit if
- You are already on treatment elsewhere and want to transfer at the dose you hold now
- You want the medication inside one price with no membership billed beside it
- You are comparing entry figures and want two of the lowest anywhere here in the set
Look elsewhere if
- You are budgeting past the promotion. The standing rate is published nowhere
- You want to know which drug you would receive. The products are named by receptor only
- You want a figure attached to a milligram. Neither one carries a dose
What it actually costs
Price as published
Two published monthly figures, both marked "starting at": $79/mo for a weekly injection the site calls a GLP-1, and $129/mo for a weekly injection it calls a GLP-1/GIP · a banner across the top of the page reads "Summer start promo applied — save $230 every month", so both figures are promotional rates already discounted, and the standing rate they discount from is published nowhere · neither molecule is named: the products are labeled by receptor — GLP-1, and GLP-1 with GIP — and while a dual GLP-1/GIP agonist is in practice tirzepatide, the page never says so and this row does not assert it · no dose sits behind either figure · the site states the medication is included in the program cost with no membership or hidden fees, and that existing patients can transfer at their current dose on proof of prescription
- Vs median
- $90/mo below the $169 median across the 242 of 373 programs we track that publish a plain monthly rate
- Market
- $59–$1300/mo is the full published spread in our ranking
- Structure
- Standard plan, self-directed low dose
No low-dose product of its own. Starting low means asking for a smaller amount inside a standard plan, at the standard plan's price.
152 of the 373 programs we track price a small dose this way. Both published figures are promotional rates the site's own banner says are already discounted, and the standing rate they discount from appears nowhere — so the first months are priced and the year is not. Neither product names its molecule: they are labeled by receptor, one GLP-1 and one GLP-1 with GIP, and this classification does not infer a drug from a mechanism. No dose sits behind either figure and no low-dose product is offered. The medication is stated to sit inside the price with no membership beside it, and an existing patient may transfer at their current dose on proof of prescription, which suits someone who has already titrated down.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
What is included
- Consult
- Included in the price
- Dietitian
- Not included
- Labs
- Not required
- Pricing
- Varies by dose, plan or tier
- Price last updated
- August 2026
What it does well
- Two of the lowest published monthly figures of any provider here, visible before intake.
- The medication is stated to be inside the price, with no membership beside it.
- An existing patient can transfer at their current dose on proof of prescription.
Pharmacy, labs and oversight
Embody does not publicly identify the pharmacy that fills its prescriptions. No bloodwork is required before you start. A clinician review is included in the price.
Transparency check
1 of 4 published openly
What Embody publishes about itself, read from its own pages when we verified them — not estimated, and not a score.
- Pharmacy named and regulatedNo pharmacy is identified anywhere we could find on its own pages.
- Not published
- A price you can read before intakeThe figure appears only after an intake quiz, so it cannot be compared before signing up.
- Not published
- What a higher dose costsPriced by dose, plan or tier, and the higher rungs are not published — the advertised figure does not tell you what a larger dose costs.
- Not published
- No FDA warning letter on fileChecked against the FDA's own warning-letter database; nothing on file for this company.
- None on file
How the program works
These are among the lowest published monthly figures of any provider here, and two things about them need saying before a reader treats them that way. The first is the banner: the site announces a summer promotion already applied to the prices shown, and quantifies it at a sum larger than either price. That makes both figures promotional, and the rate they revert to is not printed anywhere — so a reader can see what the first months cost and cannot see what the year costs. The second is what the products are called. Embody labels them by receptor rather than by drug, selling a GLP-1 injection and a GLP-1/GIP injection. In this category a dual agonist at that price point is nearly always tirzepatide, but nearly always is an inference and the page does not make the statement, so this row does not make it either. That matters more here than it would elsewhere, because the whole reason to know the molecule is to know what dose you are holding and what a small one should cost. Neither figure carries a milligram anyway. What the site does state plainly is worth the credit: the medication is inside the price rather than billed beside it, there is no membership, and a patient already on treatment elsewhere can transfer at their current dose if they can show the prescription — which is a genuinely useful policy for someone who has titrated down and wants to stay there rather than restart a ladder.
The honest cons
Both figures are promotional and the standing rate is published nowhere.
- Neither product names its molecule — they are labeled by receptor only.
- No dose sits behind either figure, and both are written as a starting point.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
How it compares
Embody is one of 373 low-dose GLP-1 programs we track, and 242 of them publish a monthly rate you can read before signing up. The ranking lists every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to.
Where this sits
#227 of 373
Ordered with the companies that pay us first, and Embody is not one of them. A disclosed partition, not a score.
Compare all 373 providers →Read this before you buy
Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.
- What microdosing GLP-1 costs
- Microdosing tirzepatide
- Is compounded GLP-1 safe?
- The true annual cost of a plan
- What a flat price costs at a low dose
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
The closest alternative
RxSpan MD
From $194/mo
- Vs median
- $25/mo above the $169 median
- Market
- $59–$1300/mo across 242 of 373
- Structure
- Standard plan, self-directed low dose
- Dispensed
- Pharmacy not publicly identified
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
Read the RxSpan MD review →Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.